Overview
Jan 1, 2008Founded1
Compare with Can Fite Biopharma, America Great Health or MEDICINOVA INC, or pick any stock.
- TickerRNAC on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersWatertown1
- Websitewww.selectabio.com
- Incorporated inDE4
- Business address7495 New Horizon Way, Frederick, Md 217034
- Filer categoryNon-accelerated filer, Smaller reporting company4
- Legal formCorporation3
- LEI529900NMN0LACZOL7C433
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered addressc/o The Corporation Trust Company, Corporation Trust Center 1209 Orange St, 19801 Wilmington, United States3
- Registered withDivision of Corporations, Department of State, 44703213
See how the biggest companies compare on our leaderboards
The Company (formerly known as Selecta Biosciences, Inc., or Selecta) was incorporated in Delaware on December 10, 2007, and is headquartered in Frederick, Maryland. On November 13, 2023, the Company and the Delaware corporation which, immediately prior to the Merger (as defined below), was known as Cartesian Therapeutics, Inc., or Old Cartesian, entered into an Agreement and Plan of Merger, or the Merger Agreement, by and among the Company, Sakura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, or First Merger Sub, Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, or Second Merger Sub, and Old Cartesian. Pursuant to the Merger Agreement, and simultaneously with execution thereof, (i) First Merger Sub merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corp…6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development86¢$58.0M
- Income tax14¢$9.2M
Out of $400.0K in revenue.7 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration and license | $400.0K | $38.3M |
| Grant | $2.4M | $638.0K |
| Total revenues | $2.8M | $38.9M |
| Research and development | $58.0M | $45.1M |
| General and administrative | $31.5M | $30.1M |
| Impairment of indefinite-lived intangible and long-lived assets | $56.7M | $7.6M |
| Total operating expenses | $146.2M | $82.8M |
| Operating loss | -$143.4M | -$43.9M |
| Interest income | $6.6M | $7.4M |
| Gain on change in fair value of warrant liabilities | $3.7M | $2.6M |
| Loss on change in fair value of contingent value right liability | -$4.4M | -$36.9M |
| Loss on change in fair value of forward contract liabilities | $0 | -$6.9M |
| Other (expense) income, net | -$2.0M | $606.0K |
| Total other income (expense), net | $3.9M | -$33.2M |
| Loss before income taxes | -$139.5M | -$77.1M |
| Income tax benefit (expense) | $9.2M | -$287.0K |
| Net loss | -$130.3M | -$77.4M |
| Foreign currency translation adjustment | $45.0K | -$21.0K |
| Total comprehensive loss | -$130.3M | -$77.4M |
| Basic (in dollars per share) | -$5.02 | -$4.48 |
| Diluted (in dollars per share) | -$5.02 | -$4.49 |
| Basic (in shares) | 26.0M shares | 17.3M shares |
| Diluted (in shares) | 26.0M shares | 17.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-10-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $125.1M | $212.6M | ||
| Accounts receivable | $1.1M | $872.0K | ||
| Prepaid expenses and other current assets | $3.0M | $3.1M | ||
| Total current assets | $129.3M | $216.6M | ||
| Property and equipment, net | $12.2M | $9.9M | ||
| Right-of-use assets, net | $5.6M | $5.5M | ||
| In-process research and development assets | $93.9M | $150.6M | ||
| Goodwill | $48.2M | $48.2M | ||
| Long-term restricted cash | $1.7M | $1.7M | ||
| Investment | $0 | $2.0M | ||
| Long-term prepaid expenses and other assets | $5.6M | $518.0K | ||
| Total assets | $296.4M | $435.0M | ||
| Accounts payable | $1.3M | $288.0K | ||
| Accrued expenses and other current liabilities | $9.5M | $12.1M | ||
| Lease liabilities | $4.2M | $2.9M | ||
| Contingent value right liability | $0 | $7.8M | ||
| Total current liabilities | $14.9M | $23.0M | ||
| Lease liabilities, net of current portion | $8.5M | $11.1M | ||
| Warrant liability | $141.0K | $3.8M | ||
| Contingent value right liability, net of current portion | $392.1M | $387.7M | ||
| Deferred tax liabilities, net | $6.9M | $16.1M | ||
| Total liabilities | $422.7M | $441.8M | ||
| Preferred stock, value, issued | $0 | $0 | ||
| Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2025 and 2024; 26,011,106 and 25,767,369 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $3.0K | ||
| Additional paid-in capital | $700.7M | $689.9M | ||
| Accumulated deficit | -$822.4M | -$692.1M | ||
| Accumulated other comprehensive loss | -$4.6M | -$4.6M | ||
| Total stockholders deficit | -$126.2M | -$6.8M | -$440.2M | |
| Total liabilities and stockholders deficit | $296.4M | $435.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 9.4M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | ||
| Common stock, shares issued (in shares) | 26.0M shares | 25.8M shares | ||
| Common stock, shares outstanding (in shares) | 26.0M shares | 25.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-10-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $125.1M | $212.6M | ||
| Accounts receivable | $1.1M | $872.0K | ||
| Prepaid expenses and other current assets | $3.0M | $3.1M | ||
| Total current assets | $129.3M | $216.6M | ||
| Property and equipment, net | $12.2M | $9.9M | ||
| Right-of-use assets, net | $5.6M | $5.5M | ||
| In-process research and development assets | $93.9M | $150.6M | ||
| Goodwill | $48.2M | $48.2M | ||
| Long-term restricted cash | $1.7M | $1.7M | ||
| Investment | $0 | $2.0M | ||
| Long-term prepaid expenses and other assets | $5.6M | $518.0K | ||
| Total assets | $296.4M | $435.0M | ||
| Accounts payable | $1.3M | $288.0K | ||
| Accrued expenses and other current liabilities | $9.5M | $12.1M | ||
| Lease liabilities | $4.2M | $2.9M | ||
| Contingent value right liability | $0 | $7.8M | ||
| Total current liabilities | $14.9M | $23.0M | ||
| Lease liabilities, net of current portion | $8.5M | $11.1M | ||
| Warrant liability | $141.0K | $3.8M | ||
| Contingent value right liability, net of current portion | $392.1M | $387.7M | ||
| Deferred tax liabilities, net | $6.9M | $16.1M | ||
| Total liabilities | $422.7M | $441.8M | ||
| Preferred stock, value, issued | $0 | $0 | ||
| Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2025 and 2024; 26,011,106 and 25,767,369 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $3.0K | ||
| Additional paid-in capital | $700.7M | $689.9M | ||
| Accumulated deficit | -$822.4M | -$692.1M | ||
| Accumulated other comprehensive loss | -$4.6M | -$4.6M | ||
| Total stockholders deficit | -$126.2M | -$6.8M | -$440.2M | |
| Total liabilities and stockholders deficit | $296.4M | $435.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 9.4M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 350.0M shares | 350.0M shares | ||
| Common stock, shares issued (in shares) | 26.0M shares | 25.8M shares | ||
| Common stock, shares outstanding (in shares) | 26.0M shares | 25.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$130.3M | -$77.4M |
| Depreciation and amortization | $3.0M | $1.2M |
| Non-cash lease expense | $778.0K | $2.4M |
| Loss on disposal of property and equipment | $0 | $273.0K |
| Impairment of indefinite-lived intangible and long-lived assets | $56.7M | $7.6M |
| Stock-based compensation expense | $10.5M | $6.6M |
| Gain on change in fair value of warrant liabilities | -$3.7M | -$2.6M |
| Loss on change in fair value of CVR liability | $4.4M | $36.9M |
| Loss on change in fair value of forward contract liabilities | $0 | $6.9M |
| Loss on impairment of investment | $2.0M | $0 |
| (Benefit) provision for deferred taxes | -$9.2M | $287.0K |
| Accounts receivable | -$243.0K | $5.0M |
| Unbilled receivable | $0 | $3.0M |
| Prepaid expenses and other assets | -$5.3M | $1.7M |
| Accounts payable | $1.1M | -$2.9M |
| Deferred revenue | $0 | -$5.8M |
| Accrued expenses and other liabilities | -$3.6M | -$6.7M |
| Net cash used in operating activities | -$73.9M | -$23.7M |
| Purchases of property and equipment | -$5.5M | -$9.1M |
| Proceeds from the sale of property and equipment | $0 | $351.0K |
| Net cash used in investing activities | -$5.5M | -$8.7M |
| Proceeds from issuance of Series A Preferred Stock, gross in private placement | $0 | $40.0M |
| Net proceeds from issuance of common stock and Series B Preferred Stock in private placement | $0 | $124.4M |
| Equity offering costs | -$624.0K | -$66.0K |
| Proceeds from exercise of common warrants | $0 | $2.9M |
| Proceeds from exercise of stock options | $323.0K | $1.2M |
| Distribution of Contingent Value Rights | -$7.8M | $0 |
| Net cash (used in) provided by financing activities | -$8.1M | $168.4M |
| Effect of exchange rate changes on cash | $45.0K | -$21.0K |
| Net change in cash, cash equivalents, and restricted cash | -$87.4M | $136.0M |
| Purchase of property and equipment not yet paid | $18.0K | $847.0K |
| Equity offering costs in accrued liabilities | $30.0K | $451.0K |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $844.0K | $5.2M |
No quarter-by-quarter statement was filed.
Compare Selecta Biosciences (United States) with another company
Corporate structure
Selecta Biosciences (United States) sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Selecta Biosciences (United States)
- Barclays Filed SCHEDULE 13G on Selecta Biosciences (United States), latest Aug 13, 2026
- JPMorgan Chase Filed SCHEDULE 13G/A on Selecta Biosciences (United States), latest Jul 22, 2026 (2 filings since Apr 25, 2025)
- FMR LLC Filed SCHEDULE 13G/A on Selecta Biosciences (United States), latest May 6, 2026 (8 filings since Feb 9, 2024)
- Murat Kalayoglu Filed SCHEDULE 13D/A on Selecta Biosciences (United States), latest Apr 2, 2026 (4 filings since Nov 22, 2023)
- Squarepoint Ops LLC Filed SCHEDULE 13G on Selecta Biosciences (United States), latest Mar 13, 2026
- Timothy A. Springer Filed SCHEDULE 13D/A on Selecta Biosciences (United States), latest Jan 15, 2025 (12 filings since Dec 15, 2021)
- Artal International S.C.A. Filed SC 13G/A on Selecta Biosciences (United States), latest Jul 12, 2024 (3 filings since Jun 12, 2023)
- Michael Singer Filed SC 13D/A on Selecta Biosciences (United States), latest Apr 10, 2024 (2 filings since Nov 22, 2023)
- MANGROVE PARTNERS IM, LLC Filed SC 13G/A on Selecta Biosciences (United States), latest Feb 14, 2024 (4 filings since May 24, 2022)
- BlackRock Filed SC 13G on Selecta Biosciences (United States), latest May 9, 2022 (2 filings since Feb 3, 2022)
- BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Selecta Biosciences (United States), latest Feb 14, 2022
- Selecta Biosciences (United States) Watertown, Massachusetts, United States
- Cartesian Bio, LLC Subsidiary · Delaware, United States
- Selecta (RUS) LLC Subsidiary · Russia
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Selecta Biosciences (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $16.9M7 Dec 31, 2025 | $12.3M7 Dec 31, 2024 | +37.9% |
| Accumulated depreciation | $4.7M7 Dec 31, 2025 | $2.4M7 Dec 31, 2024 | +100.8% |
| Property and equipment, net | $12.2M7 Dec 31, 2025 | $9.9M7 Dec 31, 2024 | +22.9% |
| Operating-lease assets (leased space) | $5.6M7 Dec 31, 2025 | $5.5M7 Dec 31, 2024 | +1.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $125.1M7 Dec 31, 2025 | $212.6M7 Dec 31, 2024 | −41.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $48.2M7 Dec 31, 2025 | $48.2M7 Dec 31, 2024 | 0% |
| Indefinite-lived intangibles (excluding goodwill) | $93.9M7 Dec 31, 2025 | $150.6M7 Dec 31, 2024 | −37.6% |
Properties, in its own words
Our corporate headquarters are currently located at 7495 New Horizon Way, Frederick, Maryland and consists of over 35,000 total square feet of integrated manufacturing and office space under a lease that expires in June 2031. Additionally, we lease approximately 7,909 total square feet of office, laboratory, and manufacturing space in Gaithersburg, Maryland under a lease that expires in January 2027 and 32,294 total square feet of office and laboratory space in Watertown, Massachusetts under a lease that expires in May 2028.
Item 2 of the 10-K filed Mar 9, 2026.6
Leadership
Who has led Selecta Biosciences (United States), and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerCarsten Brunn Dec 3, 2018 to now15
- Chief executive officerWerner Cautreels Jun 21, 2016 to Nov 14, 201716
- PresidentCarsten Brunn Dec 3, 2018 to now15
- PresidentWerner Cautreels Jun 21, 2016 to Nov 14, 201716
- Chief financial officerBlaine Davis Nov 30, 2022 to now17
- Chief financial officerKevin Tan Sep 22, 2021 to Jan 5, 202218
- Chief financial officerBradford D. Dahms Sep 5, 2019 to Jan 6, 202119
- Chief financial officerJohn Harold Leaman Oct 26, 2017 to Jun 19, 201820
- Chief financial officerDavid Siewers Jun 21, 2016 to Sep 22, 201721
- Chief operating officerMetin Kurtoglu Jan 4, 2024 to Jan 4, 202422
- Chief operating officerLloyd P. Johnston Jun 21, 2016 to Mar 19, 202123
Board members and other officers (34)
- Chief Accounting OfficerJune Ann Seymour Oct 28, 2025 to now24
- SVP, Head of ManufacturingEmily English Apr 19, 2024 to now25
- Chief Scientific OfficerChristopher M. Jewell Nov 15, 2023 to now26
- Chief Operations OfficerMetin Kurtoglu Nov 15, 2023 to now27
- Chief Medical OfficerMilos Miljkovic Nov 15, 2023 to now28
- Chief Operations OfficerLloyd P. Johnston Oct 5, 2021 to Jan 6, 202329
- Chief Medical OfficerPeter G. Traber Aug 4, 2020 to Sep 26, 202330
- ControllerAnn K. Donohue May 15, 2019 to Jun 3, 202131
- Chief Medical OfficerAlison D. Schecter Jul 17, 2019 to Jan 6, 202032
- Chief Commercial OfficerStephen Smolinski Oct 27, 2017 to Jan 6, 202033
- Chief Medical OfficerEarl Sands Jun 21, 2016 to Nov 21, 201734
- Chief Scientific OfficerTakashi Kei Kishimoto Jun 21, 2016 to Jun 1, 202335
- Board memberAdrian Ion Bot Dec 18, 2025 to now36
- Board memberKemal Malik Jul 3, 2024 to now37
- Board memberMurat Kalayoglu Nov 15, 2023 to now38
- Board memberNishan M. Desilva Jul 9, 2021 to now39
- Board memberGoran Ando Apr 28, 2020 to Jan 4, 202340
- Board memberScott Dunseth Myers Jun 18, 2019 to Nov 15, 202341
- Board memberCarrie Cox Nov 22, 2019 to now42
- Board memberCarsten Brunn Dec 3, 2018 to now15
- Board memberPatrick J. Zenner Jun 20, 2017 to now43
- Board memberAmir Nashat Jun 21, 2016 to Jun 18, 201944
- Board memberAymeric Sallin Jun 21, 2016 to Jan 4, 202445
- Board memberCarl L. Gordon Jun 21, 2016 to Jun 29, 201646
- Board memberEdwin M. Kania Jr. Jun 21, 2016 to May 16, 201747
- Board memberLeysan Shaydullina Jun 21, 2016 to Jun 21, 201648
- Board memberNoubar Afeyan Jun 21, 2016 to Jun 21, 201647
- Board memberOmid Cameron Farokhzad Jun 21, 2016 to Aug 16, 201949
- Board memberPeter Barton Hutt Jun 21, 2016 to Jun 19, 201850
- Board memberSamuel D. Isaly Jun 21, 2016 to Jun 29, 201651
- Board memberTimothy A. Springer Jun 21, 2016 to now52
- Board memberWerner Cautreels Jun 21, 2016 to Nov 14, 201716
- Board memberTimothy C. Barabe Aug 2, 2016 to now53
- General counselElona Kogan Esq. Mar 27, 2019 to Jan 6, 202054
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- SELECTA BIOSCIENCES INCJan 5, 2009 to Nov 13, 20234
Timeline
- Sep 29, 20268-K Regulation FD disclosure; Other events56
- Aug 6, 20268-K Results of operations57
- Jun 17, 20268-K Shareholder vote58
- Jun 9, 20268-K Regulation FD disclosure59
- May 26, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares60
- Apr 30, 20268-K Results of operations61
- Mar 30, 20268-K Executive or director change62
- Mar 9, 20268-K Results of operations63
- Jan 9, 20268-K Regulation FD disclosure64
- Dec 18, 20258-K Executive or director change; Code of ethics changed; Regulation FD disclosure65
- Nov 13, 20258-K Regulation FD disclosure; Other events66
- Nov 6, 20258-K Results of operations67
- Dec 3, 2018New chief executive Carsten Brunn becomes CEO15
- Jun 21, 2016New chief executive Werner Cautreels becomes CEO16
- Jan 1, 2008Founded Founded1
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.38) a share, on Nov 6, 2025.68
When it reported results
- Aug 6, 2026Reported quarterly or annual results57
- Apr 30, 2026Reported quarterly or annual results61
- Mar 9, 2026Reported quarterly or annual results63
- Nov 6, 2025Reported quarterly or annual results67
- Aug 7, 2025Reported quarterly or annual results69
- May 8, 2025Reported quarterly or annual results70
- Mar 13, 2025Reported quarterly or annual results71
- Nov 7, 2024Reported quarterly or annual results72
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
418 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 84 major events, 187 insider forms, 40 large holders, 3 private raises, 83 other. The latest 20:
- Sep 29, 20268-K EDGAR
- Aug 13, 2026SCHEDULE 13G EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 22, 2026SCHEDULE 13G/A EDGAR
- Jun 17, 20268-K EDGAR
- Jun 9, 2026144 EDGAR
- Jun 9, 20268-K EDGAR
- Jun 2, 2026144 EDGAR
- May 26, 20268-K EDGAR
- May 6, 2026SCHEDULE 13G/A EDGAR
- Apr 30, 2026S-8 EDGAR
- Apr 30, 202610-Q EDGAR
- Apr 30, 20268-K EDGAR
- Apr 28, 2026DEF 14A EDGAR
- Apr 28, 2026DEFA14A EDGAR
- Apr 6, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Apr 6, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Apr 2, 2026SCHEDULE 13D/A EDGAR
- Mar 30, 20268-K EDGAR
The 418 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
97 open-market trades by officers, directors and large owners since October 2021: 43 buys and 54 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 6, 2026 | Brunn CarstenPresident and CEO | Sale | 23,766 | $6.82 | $162.1K | Form 4 |
| Jan 6, 2026 | Miljkovic MilosChief Medical Officer | Sale | 3,573 | $6.82 | $24.4K | Form 4 |
| Jan 6, 2026 | Davis BlaineChief Financial Officer | Sale | 10,591 | $6.82 | $72.2K | Form 4 |
| Dec 4, 2025 | BARABE TIMOTHY CDirector | Buy | 30,000 | $6.86 | $205.8K | Form 4 |
| Apr 11, 2025 | SPRINGER TIMOTHY ADirector | Buy | 42,750 | $10.77 | $460.4K | Form 4 |
| Apr 10, 2025 | SPRINGER TIMOTHY ADirector | Buy | 57,170 | $10.46 | $598.3K | Form 4 |
| Apr 9, 2025 | SPRINGER TIMOTHY ADirector | Buy | 49,155 | $9.43 | $463.6K | Form 4 |
| Mar 20, 2025 | SPRINGER TIMOTHY ADirector | Buy | 54,889 | $15.59 | $855.7K | Form 4 |
| Mar 19, 2025 | SPRINGER TIMOTHY ADirector | Buy | 20,234 | $14.97 | $302.9K | Form 4 |
| Mar 18, 2025 | SPRINGER TIMOTHY ADirector | Buy | 14,740 | $14.42 | $212.6K | Form 4 |
| Jan 14, 2025 | SPRINGER TIMOTHY ADirector | Buy | 4,022 | $18.00 | $72.4K | Form 4 |
| Jan 13, 2025 | SPRINGER TIMOTHY ADirector | Buy | 16,945 | $17.35 | $294.0K | Form 4 |
| Jan 6, 2025 | Kurtoglu MetinChief Technology Officer | Sale | 2,458 | $16.83 | $41.4K | Form 4 |
| Jan 6, 2025 | Miljkovic MilosChief Medical Officer | Sale | 948 | $16.83 | $16.0K | Form 4 |
| Jan 6, 2025 | Jewell Christopher MChief Scientific Officer | Sale | 1,286 | $16.83 | $21.6K | Form 4 |
| Jan 6, 2025 | English EmilyChief Operations Officer | Sale | 906 | $16.83 | $15.2K | Form 4 |
| Jan 6, 2025 | Brunn CarstenPresident and CEO | Sale | 8,708 | $16.83 | $146.6K | Form 4 |
| Jan 6, 2025 | Davis BlaineChief Financial Officer | Sale | 4,028 | $16.83 | $67.8K | Form 4 |
| Jan 3, 2025 | Kurtoglu MetinChief Technology Officer | Sale | 2,417 | $16.72 | $40.4K | Form 4 |
| Jan 3, 2025 | Miljkovic MilosChief Medical Officer | Sale | 932 | $16.72 | $15.6K | Form 4 |
All 97 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BarclaysSCHEDULE 13G, 1 filing Aug 13, 202673
- JPMorgan ChaseSCHEDULE 13G/A, 2 filings Apr 25, 2025 to Jul 22, 202674
- FMR LLCSCHEDULE 13G/A, 8 filings Feb 9, 2024 to May 6, 202675
- Murat KalayogluSCHEDULE 13D/A, 4 filings Nov 22, 2023 to Apr 2, 202676
- Squarepoint Ops LLCSCHEDULE 13G, 1 filing Mar 13, 202677
- Timothy A. SpringerSCHEDULE 13D/A, 12 filings Dec 15, 2021 to Jan 15, 202578
- Artal International S.C.A.SC 13G/A, 3 filings Jun 12, 2023 to Jul 12, 202479
- Michael SingerSC 13D/A, 2 filings Nov 22, 2023 to Apr 10, 202480
- MANGROVE PARTNERS IM, LLCSC 13G/A, 4 filings May 24, 2022 to Feb 14, 202481
- BlackRockSC 13G, 2 filings Feb 3, 2022 to May 9, 202282
- BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 1 filing Feb 14, 202283
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Carsten BrunnPh.D. | $674.0K | $4.3M84 | |
| 2025 | Metin KurtogluM.D., Ph.D. | $163.5K | $2.5M84 | |
| 2025 | Christopher JewellPh.D. | $390.7K | $2.0M84 | |
| 2025 | Blaine Davis | 52 | $475.9K | $1.9M84 |
| 2025 | Milos MiljkovicM.D. | 42 | $439.0K | $1.7M84 |
| 2024 | President and Chief Executive Officer | $642.7K | $7.3M84 | |
| 2024 | Chief Financial Officer | $462.0K | $4.0M84 | |
| 2024 | Former Chief Technology Officer | $431.5K | $2.7M84 | |
| 2024 | Former Chief Scientific Officer | $411.9K | $1.7M84 | |
| 2024 | Chief Medical Officer | $392.3K | $1.3M84 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $190.3M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2024 | $130.0M | $130.0M |
| 2023 | $60.2M | $60.2M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 94. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Squarepoint Ops LLC | 2,254,619 | $23.5M | 0.0% | +16,133 |
| BlackRock, Inc. | 819,239 | $8.5M | 0.0% | +220,131 |
| 683 Capital Management, LLC | 650,000 | $6.8M | 0.7% | +320,000 |
| Vanguard Capital Management LLC | 555,823 | $5.8M | 0.0% | +148,226 |
| Fmr LLC | 368,429 | $3.8M | 0.0% | −431,314 |
| Geode Capital Management, LLC | 356,525 | $3.7M | 0.0% | +92,831 |
| Aqr Capital Management LLC | 356,456 | $3.7M | 0.0% | +272,436 |
| Millennium Management LLC | 309,887 | $3.2M | 0.0% | +25,570 |
| Two Sigma Investments, LP | 296,293 | $3.1M | 0.0% | +128,980 |
| State Street Corp | 249,212 | $2.6M | 0.0% | +48,875 |
| Marshall Wace, Llp | 232,919 | $2.4M | 0.0% | −18,196 |
| UBS Group AG | 208,647 | $2.2M | 0.0% | +71,807 |
| Jupiter Topco LLC | 200,905 | $2.1M | 0.0% | New |
| Privium Fund Management B.V. | 151,675 | $1.6M | 0.3% | −27,439 |
| Northern Trust Corp | 105,698 | $1.1M | 0.0% | +13,706 |
| ADAR1 Capital Management, LLC | 98,877 | $1.0M | 0.0% | New |
| Vanguard Fiduciary Trust Co | 91,854 | $957.1K | 0.0% | +21,558 |
| Vanguard Portfolio Management LLC | 87,317 | $909.8K | 0.0% | +26,734 |
| Diadema Partners LP | 87,057 | $907.1K | 0.3% | New |
| Bank Of America Corp /de/ | 84,624 | $881.8K | 0.0% | New |
| Walleye Capital LLC | 81,828 | $852.6K | 0.0% | New |
| Goldman Sachs Group Inc | 80,572 | $839.6K | 0.0% | +49,645 |
| Jump Financial, LLC | 66,800 | $696.1K | 0.0% | New |
| Bnp Paribas Financial Markets | 63,977 | $666.6K | 0.0% | +54,027 |
| Nuveen, LLC | 63,454 | $661.2K | 0.0% | +26,003 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Selecta Biosciences (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCartesian Therapeutics, Inc.2
- CIK0001453687
- Employer ID (EIN)26-16221106
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address7495 New Horizon Way, Frederick, MD 217032
- Phone301-348-86982
- Shares outstanding30,255,352 as of Jul 31, 202613
- Public float$108.7M as of Jun 30, 20256
- AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; no auditor attestation of internal control over financial reporting6
- On EDGAR sinceJan 5, 20092
- Filings874 in all: 4 (356), 8-K (172), 3 (50), 10-Q (31), SC 13D/A (29), CORRESP (19), SC 13G (19), 144 (17)2
All 46 form types
SC 13G/A (16), D (15), DEF 14A (13), DEFA14A (13), EFFECT (12), S-8 (12), UPLOAD (12), 10-K (10), CT ORDER (9), S-3 (8), SC 13D (5), SCHEDULE 13G/A (5), 4/A (4), 424B5 (4), DRS/A (4), PRE 14A (4), S-1/A (4), 424B7 (3), 8-K/A (3), SCHEDULE 13D/A (3), SCHEDULE 13G (3), POS AM (2), S-1 (2), 10-K/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-A12G (1), CERTNAS (1), D/A (1), DEFR14A (1), DRS (1), DRSLTR (1), FWP (1), NT 10-Q (1), REGDEX (1), S-1MEF (1), S-3/A (1)
- Latest filingsAnnual report (10-K) Mar 9, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Sep 29, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value per share | RNAC | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Mar 9, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks Selecta Biosciences (United States) names in Item 1A of its 10-K filed Mar 9, 2026: 45 risks under these headings, as written.6
- Risks Related to the Development of our Product Candidates
- We develop our mRNA-based product candidates by leveraging our proprietary technology and our manufacturing platform, which is an unproven approach to the treatment of autoimmune disease. We may not be successful in our efforts to build a pipeline of product candidates and develop marketable drugs.
- Clinical drug development is inherently risky and involves a lengthy and expensive process which is subject to a number of factors, many of which are outside of our control. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
- If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
- We may conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations or the complexity of regulatory burdens may otherwise adversely impact us.
- We may not be able to qualify for or obtain various designations from regulators that would have the potential to expedite the review process of one or more of our product candidates and even if we do receive one or more such designations there is no guarantee that they will ultimately expedite the process, or aid in our obtaining marketing approval or provide market exclusivity.
- Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
- Inadequate funding for the FDA and other government agencies and/or potentially shifting priorities under the new presidential administration could hinder the FDA’s and/or those other government agencies’ ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Risks Related to our Financial Position and Need for Additional Capital
- We are a development-stage company, and we expect to incur losses for the foreseeable future and may never achieve or maintain profitability.
- We will need substantial additional funding in order to complete development of our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed and on terms favorable to us, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
The other 35 risks
- Our ability to use our net operating loss and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.
- We have recorded a material amount of goodwill and indefinite-lived intangible assets in connection with the Merger. We have, and may in the future, record impairment charges, which would adversely impact our financial position and results of operations.
- We have incurred substantial expenses related to the integration of Old Cartesian.
- Risks Related to Manufacturing and our Dependence on Third-Parties
- We expect to continue to grow our manufacturing capabilities and resources and we must incur significant costs to develop this expertise and/or rely on third-parties to manufacture our products.
- We rely, and expect to continue to rely, on third-parties to conduct our clinical trials, and those third-parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials.
- Risks Related to Commercialization of our Product Candidates and Legal Compliance Matters
- Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- We currently have no sales organization. If we are unable to establish effective sales, marketing and distribution capabilities, or enter into agreements with third-parties with such capabilities, we may not be successful in commercializing our product candidates if and when they are approved.
- We face substantial competition, including from biosimilars, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
- We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.
- Even if we are able to commercialize any of our product candidates, the products may become subject to unfavorable pricing regulations or third-party coverage or reimbursement policies, any of which would have a material adverse effect on our business.
- Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
- Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
- Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
- We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can have a material adverse effect on our business.
- If we or third-parties we rely upon fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
- Risks Related to our Intellectual Property
- If we or our licensors are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.
- If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive position would be harmed.
- Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, and our issued patents covering our product candidates could be found invalid or unenforceable or could be interpreted narrowly if challenged in court.
- The lives of our patents may not be sufficient to effectively protect our products and business.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
- We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
- We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
- We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.
- If we do not obtain additional protection under the Hatch-Waxman Act and similar foreign legislation extending the terms of our patents for our product candidates, our business may be harmed.
- Risks Related to our Operations
- Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
- We have incurred increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices.
- A variety of risks associated with winding down operations of our subsidiary in Russia or expanding operations internationally could adversely affect our business.
- Our business and operations, including our development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or third-parties on which we rely, including our CROs or other contractors or consultants.
- Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business.
- Risks Related to our Common Stock
- The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
- Our executive officers, directors, and principal stockholders, if they choose to act together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval.
- Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.
- We have been in the past and may in the future be subject to stockholder litigation.
Links
- Websitewww.selectabio.com1
- WikidataQ30288672
- SEC EDGARCIK 1453687
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARKevin Tan, Chief financial officer
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31SEC EDGARAnn K. Donohue, Controller
- 32
- 33
- 34SEC EDGAREarl Sands, Chief Medical Officer
- 35
- 36SEC EDGARAdrian Ion Bot, Board member
- 37SEC EDGARKemal Malik, Board member
- 38SEC EDGARMurat Kalayoglu, Board member
- 39SEC EDGARNishan M. Desilva, Board member
- 40SEC EDGARGoran Ando, Board member
- 41SEC EDGARScott Dunseth Myers, Board member
- 42SEC EDGARCarrie Cox, Board member
- 43SEC EDGARPatrick J. Zenner, Board member
- 44SEC EDGARAmir Nashat, Board member
- 45SEC EDGARAymeric Sallin, Board member
- 46SEC EDGARCarl L. Gordon, Board member
- 47SEC EDGAREdwin M. Kania Jr., Board member
- 48SEC EDGARLeysan Shaydullina, Board member
- 49SEC EDGAROmid Cameron Farokhzad, Board member
- 50SEC EDGARPeter Barton Hutt, Board member
- 51SEC EDGARSamuel D. Isaly, Board member
- 52SEC EDGARTimothy A. Springer, Board member
- 53SEC EDGARTimothy C. Barabe, Board member
- 54SEC EDGARElona Kogan Esq., General counsel
- 55
- 56
- 57SEC EDGARResults of operations
- 58SEC EDGARShareholder vote
- 59SEC EDGARRegulation FD disclosure
- 60
- 61SEC EDGARResults of operations
- 62SEC EDGARExecutive or director change
- 63SEC EDGARResults of operations
- 64SEC EDGARRegulation FD disclosure
- 65
- 66
- 67SEC EDGARResults of operations
- 68NasdaqNasdaq calendar
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85